 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
The current sources are secondary, am in the process of adding citations to originating studies. Brandonazz (talk) 02:31, 18 February 2021 (UTC)
- @Brandonazz: Note that unlike academic publications, Wikipedia prefers secondary sources, as they help to support the case for independent peer-reviewed notability. See WP:SCHOLARSHIP. Klbrain (talk) 10:01, 1 September 2021 (UTC)
Merger proposal edit
The section Antibe Therapeutics#Products contains much on the development of this drug that would be better placed here, so I support the February proposal to do so. Klbrain (talk) 10:09, 1 September 2021 (UTC)
- I'm not sure Antibe is notable, so I would instead suggest a merge into this article. Suriname0 (talk) 20:08, 14 September 2023 (UTC)
- Given that Antibe is now a listed company and has another drugs in development (ATB-352 and ATB-340), I think that it may well warrant separate coverage, and that readers are best served by having them list separately. However, it would be reasonable to move some of the material from Antibe Therapeutics, which is why the split section was the appropriate proposal. Klbrain (talk) 21:26, 15 September 2023 (UTC)
- I see. Well, I think you can just complete the move if you want; it's clearly not a high-traffic page, with no opposes in 2 years. Suriname0 (talk) 23:19, 15 September 2023 (UTC)
- Given that Antibe is now a listed company and has another drugs in development (ATB-352 and ATB-340), I think that it may well warrant separate coverage, and that readers are best served by having them list separately. However, it would be reasonable to move some of the material from Antibe Therapeutics, which is why the split section was the appropriate proposal. Klbrain (talk) 21:26, 15 September 2023 (UTC)